Medindia

X

Morepan to file new drug applications with the USFDA

by Medindia Content Team on  January 15, 2002 at 5:27 PM Drug News   - G J E 4
Morepan to file new drug applications with the USFDA
Domestic pharma major Morepen Labs is planning to file its nine abbreviated new drug applications (ANDA) with the US FDA by the year 2003. The company would file its first two ANDAs - Loratadine (anthistatminic drug) and Atorvastain Calcium (anti-cholesterol) - by the end of 2002. Loratadine is the third-largest selling drug in the world.
Advertisement

Currently, Morepen's ANDAs pipeline has Loratadine, Fexofenadine Hydrochloride (antihistaminic), Atrovastain Calcium, Fluvastain Sodium (anti-cholesterol), Zafirlukast (antiasthamatic), Cisapride BP (gastro pro-kinetic), Sultamicillin Tosylate (anti-bacterial), Sultamicillin Base (anti-bacterial) and Sulbactam Sodium (anti-bacterial).

Advertisement
Morepen Labs CMD Sushil Suri said his company will file the ANDAs through its new joint venture subsidiary with the US-based Drugmax Inc. Recently, Morepen Labs had floated a special-purpose vehicle in joint venture with Drugmax to tap the $200-billion US generic market.

Drugmax provides the necessary support and guides how to file for the ANDA, which is required for generic finished dosage form under the US regulatory system. Morepen is setting up formulation manufacturing facilities, in accordance with the USFDA guidelines.

Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All